Targeting a specific protein to treat aggressive lymphomas
Therapeutic targeting of SIRT3 for aggressive and refractory lymphomas
This study is looking at a type of aggressive lymphoma called Diffuse Large B-Cell Lymphoma (DLBCL) and is testing a new way to help treat it by targeting a protein that helps the cancer cells grow, with the hope that this will make the cancer cells die and work better with current treatments.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Weill Medical Coll of Cornell Univ NIH-funded |
| Lab location | 1 site (New York, United States) |
| Project ID | NIH-11035242 on NIH RePORTER |
What this research studies
This research focuses on aggressive lymphomas, particularly Diffuse Large B-Cell Lymphomas (DLBCLs), which require significant metabolic resources for growth. The study investigates the role of a protein called SIRT3, which regulates metabolism in these cancer cells. By disrupting SIRT3 function, the researchers aim to induce cell death in lymphoma cells, utilizing a specially designed compound that mimics the effects of SIRT3 loss. The research also explores how this approach can be combined with existing therapies to enhance treatment effectiveness.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with aggressive lymphomas, particularly those with Diffuse Large B-Cell Lymphomas (DLBCLs).
Not a fit: Patients with lymphomas that are not classified as aggressive or those who do not have Diffuse Large B-Cell Lymphomas may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatments for patients with aggressive lymphomas, potentially improving survival rates.
How similar studies have performed: Other research has shown promising results in targeting metabolic pathways in cancer treatment, suggesting that this approach could be effective.
Where this research is happening
New York, United States
- Weill Medical Coll of Cornell Univ — New York, United States (Active)
Researchers
- Principal investigator: Li, Meng — Weill Medical Coll of Cornell Univ
- Study coordinator: Li, Meng
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.